Finally, NOX4-overexpressing cells were tested for survival benefit and response to dual-checkpoint immunotherapy (anti-PD-1/anti-CTLA-4).<h4>Results</h4>NOX4 deletion accelerated tumor growth <i>in vivo</i> and enhanced proliferation, colony formation, and migratory capacity <i>in vitro</i>. Here, CTLA4 is linked to neoplasm.